# Sectoral Asset Management

> Sectoral Asset Management is a VC fund backing Health Care and Biotechnology. See 62 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Montréal, Canada
- Total investments: 62
- Last investment: Apr 2026
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/106663?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A106663%2Cidx%3A1-1-1%2CtarId%3A1441126995661%2Ctas%3ASectoral%20Asset%20Management
- Website: http://www.sectoral.com

Sectoral Asset Management is a VC fund in Montréal focused on Health Care and Biotechnology. Sectoral Asset Management Inc. is an industry-leading specialist in managing global investment portfolios in the healthcare sector. Sectoral maintains offices in Montreal and Geneva and is a proud member of the State Street Global Alliance. They currently manage approximately US $4.0 billion in assets.

## Contacts

5 contacts available for Sectoral Asset Management. Shizune tracks 9 team members at Sectoral Asset Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sectoral-asset-management?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $20M–$84M |
| Series C | $39M–$139M |
| Post-IPO Equity | $23M–$230M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 31 | 50% |
| Biotechnology | 27 | 44% |
| Medical | 22 | 35% |
| Therapeutics | 16 | 26% |
| Medical Device | 13 | 21% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 19 | 31% |
| Series C | 14 | 23% |
| Post-IPO Equity | 6 | 10% |
| Series D | 5 | 8% |
| Series A | 3 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 32 | 52% |
| United Kingdom | 4 | 6% |
| France | 2 | 3% |
| Israel | 1 | 2% |
| Sweden | 1 | 2% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Marc Andre Marcotte | Managing Director & Head of Research | 9 | https://shizune.co/investors/profile/marc-andre-marcotte |
| Alex Bernal | IT Manager | 0 | https://shizune.co/investors/profile/alex-bernal |
| Dimo Vodenitcharov | Network Administrator | 0 | https://shizune.co/investors/profile/dimo-vodenitcharov |
| Guillaume Aquin | Senior Manager Trading & Operations | 0 | https://shizune.co/investors/profile/guillaume-aquin |
| Justin Gelinas | Operations Manager | 0 | https://shizune.co/investors/profile/justin-gelinas |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Route 92 Medical | Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $50M | Private Equity | Apr 07, 2026 |  |
| SecondWave Systems | SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppressesneural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders. |  | Series A | Oct 22, 2025 |  |
| Iantrek | Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M | Series C | Aug 20, 2025 |  |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M | Series D | Jul 09, 2025 |  |
| Shoulder Innovations | Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $40M | Series E | Mar 10, 2025 |  |
| Evommune | Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $115M | Series C | Oct 31, 2024 |  |
| LENZ Therapeutics | LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. | $53.5M | Post-IPO Equity | Mar 21, 2024 |  |
| Phagenesis | Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $42M | Series D | Mar 04, 2024 |  |
| Cagent Vascular | Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $30M | Series C | Feb 20, 2024 |  |
| Noctrix Health | Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. | $40M | Series C | Jan 16, 2024 |  |

10 of 62 investments shown.

## Co-investors
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 9 deals together
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 9 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 8 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 7 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 7 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Life Science Investors in Middle East](https://shizune.co/investors/life-science-investors-middle-east)
- [Life Science VC Funds in Middle East](https://shizune.co/investors/life-science-vc-funds-middle-east)
- [Life Science VC Funds in Israel](https://shizune.co/investors/life-science-vc-funds-israel)

## FAQ

### What does Sectoral Asset Management invest in?

Sectoral Asset Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 62 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sectoral Asset Management's check size?

Sectoral Asset Management typically joins rounds of $20M–$84M at Series B, $39M–$139M at Series C and $23M–$230M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sectoral Asset Management participates in.

### How do I contact Sectoral Asset Management?

Public channels for Sectoral Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sectoral Asset Management?

The team at Sectoral Asset Management includes Marc Andre Marcotte (Managing Director & Head of Research), Alex Bernal (IT Manager) and Dimo Vodenitcharov (Network Administrator), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co